Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities

References

1. 1.↵
   1. Honce JM,
   2. Nagae L,
   3. Nyberg E

   . Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int 2015;2015:e809252 doi:10.1155/2015/809252 pmid:26483978

   CrossRefPubMed
2. 2.↵
   1. Wattjes MP,
   2. Vennegoor A,
   3. Steenwijk MD, et al

   . MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 2015;86:793–98 doi:10.1136/jnnp-2014-308630 pmid:25205744

   Abstract/FREE Full Text
3. 3.↵
   1. Rong L,
   2. Li N,
   3. Zhang Z

   . Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res 2022;41:142 doi:10.1186/s13046-022-02349-7 pmid:35428347

   CrossRefPubMed
4. 4.↵
   1. Sperling RA,
   2. Jack CR,
   3. Black SE, et al

   . Amyloid related imaging abnormalities (ARIA) in amyloid modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367–85 doi:10.1016/j.jalz.2011.05.2351 pmid:21784348

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Barakos J,
   2. Sperling R,
   3. Salloway S, et al

   . MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 2013;34:1958–65 doi:10.3174/ajnr.A3500 pmid:23578674

   Abstract/FREE Full Text
6. 6.↵
   1. Salloway S,
   2. Chalkias S,
   3. Barkhof F, et al

   . Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 2022;79:13–21 doi:10.1001/jamaneurol.2021.4161 pmid:34807243

   CrossRefPubMed
7. 7.↵
   1. Salloway S,
   2. Sperling R,
   3. Fox NC, et al

   ; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322–33 doi:10.1056/NEJMoa1304839 pmid:24450891

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Ostrowitzki S,
   2. Lasser RA,
   3. Dorflinger E, et al

   . A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther 2017;9:95 doi:10.1186/s13195-017-0318-y pmid:29221491

   CrossRefPubMed
9. 9.↵
   1. Swanson CJ,
   2. Zhang Y,
   3. Dhadda S, et al

   . A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimers disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer. Res & Ther 2021;13:80 doi:10.1186/s13195-021-00813-8 pmid:33865446

   CrossRefPubMed
10. 10.↵
    1. Doody RS,
    2. Thomas RG,
    3. Farlow M, et al

    ; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:311–21 doi:10.1056/NEJMoa1312889 pmid:24450890

    CrossRefPubMedWeb of Science
11. 11.↵
    1. van Dyck CH,
    2. Swanson CJ,
    3. Aisen P, et al

    . Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9–21 doi:10.1056/NEJMoa2212948 pmid:36449413

    CrossRefPubMed
12. 12.↵
    1. Mintun MA,
    2. Lo AC,
    3. Duggan Evans C, et al

    . Donanemab in early Alzheimer’s disease. N Engl J Med 2021;384:1691–704 doi:10.1056/NEJMoa2100708 pmid:33720637

    CrossRefPubMed
13. 13.↵
    1. Greenberg SM,
    2. Bacskai BJ,
    3. Hernandez-Guillamon M, et al

    . Cerebral amyloid angiopathy and Alzheimer disease: one peptide, two pathways. Nat Rev Neurol 2020;16:30–42 doi:10.1038/s41582-019-0281-2 pmid:31827267

    CrossRefPubMed
14. 14.↵
    1. Zago W,
    2. Schroeter S,
    3. Guido T, et al

    . Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement 2013;9:S105–15 doi:10.1016/j.jalz.2012.11.010 pmid:23583235

    CrossRefPubMed
15. 15.↵
    1. Carlson C,
    2. Siemers E,
    3. Hake A, et al

    . Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer’s disease. Alzheimers Dement (Amst) 2016;2:75–85 doi:10.1016/j.dadm.2016.02.004 pmid:27239538

    CrossRefPubMed
16. 16.↵
    1. VandeVrede L,
    2. Gibbs DM,
    3. Koestler M, et al

    . Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement (Amst) 2020;12:e12101 doi:10.1002/dad2.12101 pmid:33072846

    CrossRefPubMed
17. 17.↵
    1. Reish NJ,
    2. Jamshidi P,
    3. Stamm B, et al

    . Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 2023;388:478–79 doi:10.1056/NEJMc2215148 pmid:36599061

    CrossRefPubMed
18. 18.↵
    1. Sevigny J,
    2. Chiao P,
    3. Bussière T, et al

    . The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50–56 doi:10.1038/nature19323 pmid:27582220

    CrossRefPubMed
19. 19.↵
    1. Cummings J,
    2. Apostolova L,
    3. Rabinovici GD, et al

    . Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 2023;10:362–77 doi:10.14283/jpad.2023.30 pmid:37357276

    CrossRefPubMed
20. 20.↵
    1. Cummings J,
    2. Rabinovici GD,
    3. Atri A, et al

    . Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis 2022;9:221–30 doi:10.14283/jpad.2022.34 pmid:35542993

    CrossRefPubMed
21. 21.↵
    1. Cogswell PM,
    2. Barakos JA,
    3. Barkhof F, et al

    . Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol 2022;43:E19–35 doi:10.3174/ajnr.A7586 pmid:35953274

    Abstract/FREE Full Text
22. 22.↵
    1. Campbell MR,
    2. Ashrafzadeh‐Kian S,
    3. Petersen RC, et al

    . P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement (Amst) 2021;13:e12190 doi:10.1002/dad2.12190 pmid:34027020

    CrossRefPubMed
23. 23.↵
    1. Hansson O,
    2. Blennow K,
    3. Zetterberg H, et al

    . Blood biomarkers for Alzheimer’s disease in clinical practice and trials. Nat Aging 2023;3:506–19 doi:10.1038/s43587-023-00403-3 pmid:37202517

    CrossRefPubMed
24. 24.↵
    1. Pittock RR,
    2. Aakre JA,
    3. Castillo AM, et al

    . Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology 2023;101:e1837–49 doi:10.1212/WNL.0000000000207770 pmid:37586881

    CrossRefPubMed
25. 25.↵
    ADUHELM (aducanumab-avwa) is FDA approved. https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease. Accessed August 1, 2023
26. 26.↵
    Drugs@FDA: FDA-Approved Drugs. https://www.fda.gov/drugs/drug-approvals-and-databases/about-drugsfda. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed July 1, 2024
27. 27.↵
    1. Ramanan VK,
    2. Armstrong MJ,
    3. Choudhury P, et al

    ; AAN Quality Committee. Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology. Neurology 2023;101:842–52 doi:10.1212/WNL.0000000000207757 pmid:37495380

    Abstract/FREE Full Text
28. 28.↵
    1. Nandigam RN,
    2. Viswanathan A,
    3. Delgado P, et al

    . MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 2009;30:338–43 doi:10.3174/ajnr.A1355 pmid:19001544

    Abstract/FREE Full Text
29. 29.↵
    1. Kallmes DF,
    2. Hui FK,
    3. Mugler JP

    . Suppression of cerebrospinal fluid and blood flow artifacts in FLAIR MR imaging with a single-slab three-dimensional pulse sequence: initial experience. Radiology 2001;221:251–55 doi:10.1148/radiol.2211001712 pmid:11568348

    CrossRefPubMed
30. 30.↵
    1. Fazekas F,
    2. Chawluk J,
    3. Alavi A, et al

    . MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987;149:351–56 doi:10.2214/ajr.149.2.351 pmid:3496763

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Polak D,
    2. Cauley S,
    3. Huang SY, et al

    . A highly-accelerated volumetric brain examination using optimized wave-CAIPI encoding. J Magn Reson Imaging 2019;50:961–74 doi:10.1002/jmri.26678 pmid:30734388

    CrossRefPubMed
32. 32.↵
    1. Bash S,
    2. Wang L,
    3. Airriess C, et al

    . Deep learning enables 60% accelerated volumetric brain MRI while preserving quantitative performance: a prospective, multicenter, multireader trial. AJNR Am J Neuroradiol 2021;42:2130–37 doi:10.3174/ajnr.A7358 pmid:34824098

    Abstract/FREE Full Text